Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$144.14

2.25 (1.59%)

, ABBV

AbbVie

$100.24

0.75 (0.75%)

04:55
01/10/18
01/10
04:55
01/10/18
04:55

Jefferies to hold healthcare events

Jefferies Healthcare Events including a cocktail reception and dinners with ABBV, RARX, SRGY andf SPPI in San Francisco on January 7-10.

JNJ

Johnson & Johnson

$144.14

2.25 (1.59%)

ABBV

AbbVie

$100.24

0.75 (0.75%)

RARX

RA Pharmaceuticals

$8.49

0.05 (0.59%)

SPPI

Spectrum

$18.59

0.56 (3.11%)

  • 10

    Jan

  • 10

    Jan

  • 23

    Jan

  • 16

    Feb

JNJ Johnson & Johnson
$144.14

2.25 (1.59%)

01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/18
JPMS
01/02/18
DOWNGRADE
Target $150
JPMS
Neutral
Johnson & Johnson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72. The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however. Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
12/13/17
LEER
12/13/17
NO CHANGE
Target $120
LEER
Outperform
Myeloma data good for Johnson & Johnson, neutral to Celgene, says Leerink
Leerink analyst Geoffrey Porges notes that during the late breaking abstract session at ASH a "very impressive" dataset was presented highlighting that the addition of Darzalex to standard of care combination VMP improves survival outcomes in newly diagnosed myeloma patients who are ineligible for transplant. The analyst points out that it is no secret that Johnson & Johnson (JNJ) would like to move daratumumab into frontline therapy in myeloma, and this trial is its best near-term opportunity. Porges believes that the trial success is positive for Johnson & Johnson/daratumumab and neutral for Celgene (CELG)/Revlimid. He reiterates an Outperform rating and $120 price target on Celgene's shares.
ABBV AbbVie
$100.24

0.75 (0.75%)

01/02/18
RBCM
01/02/18
DOWNGRADE
RBCM
Sector Perform
Enanta downgraded to Sector Perform at RBC Capital after 'considerable run'
As reported earlier, RBC Capital analyst Brian Abrahams downgraded Enanta (ENTA) to Sector Perform from Outperform, saying his positive near-term thesis on Mavyret has now played out and the potential for long-term royalties from AbbVie (ABBV) are "baked into the stock". The analyst believes that the trajectory of the treatment is now better appreciated" by the Street, adding the stock is more likely to trade in line in the immediate term given the "limited patient data for the NASH/PBC and RSV programs in 2018".
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
AbbVie joining peers with typical January price hikes, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss noted that AbbVie (ABBV) took early-January price increases, highlighting that Humira saw a 9.7% increase that is similar in both timing and magnitude to last year's increase and once again "exactly" matches Amgen's (AMGN) Enbrel. In a note of his own earlier this morning titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs," Piper Jaffray analyst Christopher Raymond highlighted that Amgen and Biogen (BIIB) also increased prices on a number of important franchise products effective January 1, 2018. Purkiss maintains his Overweight rating on AbbVie shares.
01/04/18
JEFF
01/04/18
NO CHANGE
Target $120
JEFF
Buy
Jefferies calls AbbVie top pick in Pharma, ups target to $120
Jefferies analyst Jeffrey Holford raised his price target for AbbVie to $120 from $115 and says the stock is his top pick in U.S. Large Cap Pharma. Positive estimate revisions tied to tax reform, the Mavyret launch and share repurchases put the company "in a strong position" to beat and raise through 2018, Holford tells investors in a research note. He believes the company's 2018 guidance is likely too conservative.
12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
RARX RA Pharmaceuticals
$8.49

0.05 (0.59%)

12/04/17
BMOC
12/04/17
NO CHANGE
Target $34
BMOC
Outperform
RA Pharmaceuticals price target raised to $34 from $31 at BMO Capital
12/04/17
12/04/17
NO CHANGE
Target $34

Outperform
RA Pharmaceuticals price target raised after trial success at BMO Capital
As previously reported, BMO Capital analyst M. IanSomaiya raised his price target for RA Pharmaceuticals to $34 from $31, while reiterating an Outperform rating, after its RA101495 demonstrated clinical benefit in all three cohorts in the ongoing Phase 2 paroxysmal nocturnal hemoglobinuria trial. The analyst believes phase 3 design is rational and likely to succeed.
12/04/17
JEFF
12/04/17
NO CHANGE
Target $25
JEFF
Buy
RA Pharmaceuticals selloff 'way too overdone,' says Jefferies
Jefferies analyst Eun Yang views the post-Phase 2 data selloff today in shares of RA Pharmaceuticals (RARX) as overreaction. The interim data show RA's RA101495 is an active and approvable product with efficacy as good as Alexion's (ALXN) Soliris, Yang tells investors in an intraday research note. While RA101495 may not be suitable for the 20% of Soliris patients that are transfusion dependent, the 37% selloff in the stock today is "way too overdone," the analyst contends. Yang sees "significant upside potential" in RA shares even at "modest market share of Soliris." She keeps a Buy rating on RA Pharmaceuticals with a $25 price target. The stock in midday trading is down $5.34 to $8.89.
12/04/17
12/04/17
NO CHANGE
Target $170

Overweight
RA data 'underwhelms' compared to Alexion's Soliris, says Piper Jaffray
Today's paroxysmal nocturnal hemoglobinuria data from RA Pharmaceuticals (RARX) "underwhelms on efficacy" in comparison to Alexion's (ALNX) Soliris "and for that matter" ALXN1210, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Remind Us Again... Why Are We Worried About Ra Pharmaceuticals?" The analyst believes inferior efficacy to Soliris should put "to bed" the treat from RA, and he reminds investors that ALXN1210 "should raise the bar from a convenience standpoint." The analyst sees "little reason to fret" at this point over the competitive threat to Alexion from RA101495. Raymond keeps an Overweight rating on Alexion with a $170 price target.
SPPI Spectrum
$18.59

0.56 (3.11%)

10/20/17
JEFF
10/20/17
NO CHANGE
Target $25
JEFF
Buy
Spectrum price target raised to $25 from $18 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Spectrum Pharmaceuticals to $25 saying the Phase II data in EGFR exon 20, while early, are "incrementally de-risking and suggest a potent/tolerable drug." The shares can "grind higher" into the first half of 2018, the analyst contends. He keeps a Buy rating on Spectrum.
12/21/17
JEFF
12/21/17
NO CHANGE
Target $25
JEFF
Buy
Spectrum study still enrolling, clinicaltrials.gov is wrong, says Jefferies
sppiJefferies analyst Matthew Andrews says the clinicaltrials.gov listing that shows enrolling halted for Spectrum Pharmaceuticals' poziotinib study in advanced non-small cell lung cancer is wrong. The analyst spoke to a member of the International Cancer Advocacy Network Exon 20 Advisory Council and learned that 50-55 patients have been enrolled and 30 are being actively screened. This is consistent with Spectrum and Dr. Heymach's comments that an error was made in updating clinicaltrials.gov, Andrews tells investors in a research note. The analyst has a Buy rating on Spectrum shares with a $25 price target. The stock closed yesterday down 33c to $16.68.
12/18/17
RILY
12/18/17
INITIATION
Target $26
RILY
Buy
Spectrum initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started Spectrum Pharmaceuticals with a Buy rating and $26 price target.
10/23/17
GUGG
10/23/17
INITIATION
Target $32
GUGG
Buy
Spectrum initiated with a Buy at Guggenheim
Guggenheim initiated Spectrum with a Buy and $32 price target.

TODAY'S FREE FLY STORIES

SNE

Sony

$48.38

-0.22 (-0.45%)

20:47
05/21/18
05/21
20:47
05/21/18
20:47
Hot Stocks
Sony targets operating cash flow of Y2T as part of its mid-range plan »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

BOFI

BofI Holding

$41.97

0.29 (0.70%)

20:40
05/21/18
05/21
20:40
05/21/18
20:40
Downgrade
BofI Holding rating change at Compass Point »

BofI Holding downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 24

    Sep

SNE

Sony

$48.38

-0.22 (-0.45%)

20:32
05/21/18
05/21
20:32
05/21/18
20:32
Hot Stocks
Sony confirms to acquire 60% equity interest in DH Publishing which manages EMI »

Mubadala Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$48.38

-0.22 (-0.45%)

20:25
05/21/18
05/21
20:25
05/21/18
20:25
Conference/Events
Sony to hold IR Day 2018 »

Sony IR Day 2018 to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

TJX

TJX

$84.66

-0.15 (-0.18%)

, AZO

AutoZone

$665.68

13.03 (2.00%)

20:25
05/21/18
05/21
20:25
05/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$84.66

-0.15 (-0.18%)

AZO

AutoZone

$665.68

13.03 (2.00%)

KSS

Kohl's

$65.47

1.79 (2.81%)

AAP

Advance Auto Parts

$119.18

0.93 (0.79%)

EV

Eaton Vance

$58.05

0.52 (0.90%)

TOL

Toll Brothers

$43.60

0.43 (1.00%)

IGT

International Game

$29.75

-0.655 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 24

    May

  • 24

    May

ADBE

Adobe

$238.00

-0.04 (-0.02%)

19:54
05/21/18
05/21
19:54
05/21/18
19:54
Recommendations
Adobe analyst commentary at JPMorgan »

Adobe adds the missing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$48.38

-0.22 (-0.45%)

19:36
05/21/18
05/21
19:36
05/21/18
19:36
Periodicals
Breaking Periodicals news story on Sony »

Sony to buy out remaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

K

Kellogg

$60.77

0.58 (0.96%)

19:28
05/21/18
05/21
19:28
05/21/18
19:28
Conference/Events
Kellogg management to meet with JPMorgan »

Meetings to be held New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 25

    May

ST

Sensata

$52.58

(0.00%)

19:24
05/21/18
05/21
19:24
05/21/18
19:24
Earnings
Sensata backs FY18 EPS view $3.57-$3.73 following valves business sale »

Consensus $3.66. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

ST

Sensata

$52.58

(0.00%)

19:22
05/21/18
05/21
19:22
05/21/18
19:22
Hot Stocks
Sensata enters $173M deal to sell its valves business to Pacific Industrial Co »

Sensata Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

ELLI

Ellie Mae

$104.16

0.35 (0.34%)

19:20
05/21/18
05/21
19:20
05/21/18
19:20
Conference/Events
Ellie Mae management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 12

    Jun

FB

Facebook

$184.48

1.79 (0.98%)

19:19
05/21/18
05/21
19:19
05/21/18
19:19
Periodicals
U.K. lawmakers seek answers from Facebook CEO on data misuse, Reuters says »

U.K. lawmakers want…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

BA

Boeing

$363.95

12.71 (3.62%)

19:18
05/21/18
05/21
19:18
05/21/18
19:18
Periodicals
Boeing Charleston workers to vote on union representation on May 31, WSJ says »

The U.S. National Labor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ESLOY

Essilor

$0.00

(0.00%)

19:17
05/21/18
05/21
19:17
05/21/18
19:17
Conference/Events
Essilor management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WIX

Wix.com

$85.45

-3.25 (-3.66%)

, SHOP

Shopify

$144.58

-2.45 (-1.67%)

19:06
05/21/18
05/21
19:06
05/21/18
19:06
Recommendations
Wix.com, Shopify, Adobe analyst commentary at JPMorgan »

After Magento deal, Adobe…

WIX

Wix.com

$85.45

-3.25 (-3.66%)

SHOP

Shopify

$144.58

-2.45 (-1.67%)

ADBE

Adobe

$238.00

-0.04 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

MU

Micron

$55.48

2.11 (3.95%)

19:05
05/21/18
05/21
19:05
05/21/18
19:05
Conference/Events
Micron management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 30

    May

GSM

Ferroglobe

$11.35

0.36 (3.28%)

, CRMT

America's Car-Mart

$54.60

-0.05 (-0.09%)

19:00
05/21/18
05/21
19:00
05/21/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

GSM

Ferroglobe

$11.35

0.36 (3.28%)

CRMT

America's Car-Mart

$54.60

-0.05 (-0.09%)

MU

Micron

$55.48

2.11 (3.95%)

MUFG

Mitsubishi UFJ

$6.45

-0.01 (-0.15%)

AKAM

Akamai

$76.46

1.13 (1.50%)

ADBE

Adobe

$238.00

-0.04 (-0.02%)

PSTG

Pure Storage

$23.60

-0.065 (-0.27%)

NDSN

Nordson

$139.50

4.45 (3.30%)

IGT

International Game

$29.75

-0.655 (-2.15%)

LBY

Libbey

$6.84

-0.27 (-3.80%)

ARDX

Ardelyx

$5.65

-0.15 (-2.59%)

SAIL

SailPoint

$22.43

-0.16 (-0.71%)

CADE

Cadence Bancorp

$29.07

0.01 (0.03%)

TWOU

2U

$95.50

-0.16 (-0.17%)

MYOK

MyoKardia

$48.30

-3.45 (-6.67%)

SHOP

Shopify

$144.58

-2.45 (-1.67%)

AIR

AAR Corp.

$47.70

0.74 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 24

    May

  • 30

    May

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 26

    Jun

  • 10

    Jul

  • 10

    Sep

  • 24

    Sep

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 24

    May

AVA

Avista

$52.62

0.07 (0.13%)

18:55
05/21/18
05/21
18:55
05/21/18
18:55
Hot Stocks
CFIUS says no unresolved security concerns over Hydro One-Avista deal »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEST

Destination Maternity

$2.68

-0.03 (-1.11%)

18:40
05/21/18
05/21
18:40
05/21/18
18:40
Hot Stocks
Investors say Destination Maternity needs 'fresh perspectives' »

Nathan G. Miller and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ARWR

Arrowhead

$9.78

-0.21 (-2.10%)

18:35
05/21/18
05/21
18:35
05/21/18
18:35
Conference/Events
Arrowhead management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

JHX

James Hardie

$17.32

(0.00%)

18:31
05/21/18
05/21
18:31
05/21/18
18:31
Earnings
James Hardie reports FY18 net profit $146.1M vs. $276.5M last year »

Reports FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$90.13

0.88 (0.99%)

18:27
05/21/18
05/21
18:27
05/21/18
18:27
Conference/Events
West Pharmaceutical management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

  • 19

    Jun

SSRM

SSR Mining

$10.30

0.02 (0.19%)

18:20
05/21/18
05/21
18:20
05/21/18
18:20
Conference/Events
SSR Mining management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

PDCE

PDC Energy

$65.33

1.57 (2.46%)

18:18
05/21/18
05/21
18:18
05/21/18
18:18
Hot Stocks
PDC Energy Amidon sells 8,045 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

GSM

Ferroglobe

$11.35

0.36 (3.28%)

18:15
05/21/18
05/21
18:15
05/21/18
18:15
Conference/Events
Ferroglobe management to meet with Jefferies »

Meeting to be held in w…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.